| pubmed-article:17107906 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17107906 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:17107906 | lifeskim:mentions | umls-concept:C0026764 | lld:lifeskim |
| pubmed-article:17107906 | lifeskim:mentions | umls-concept:C0025815 | lld:lifeskim |
| pubmed-article:17107906 | lifeskim:mentions | umls-concept:C0040736 | lld:lifeskim |
| pubmed-article:17107906 | lifeskim:mentions | umls-concept:C0039736 | lld:lifeskim |
| pubmed-article:17107906 | lifeskim:mentions | umls-concept:C0010583 | lld:lifeskim |
| pubmed-article:17107906 | lifeskim:mentions | umls-concept:C0011777 | lld:lifeskim |
| pubmed-article:17107906 | lifeskim:mentions | umls-concept:C0013089 | lld:lifeskim |
| pubmed-article:17107906 | lifeskim:mentions | umls-concept:C0042679 | lld:lifeskim |
| pubmed-article:17107906 | lifeskim:mentions | umls-concept:C0332152 | lld:lifeskim |
| pubmed-article:17107906 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:17107906 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:17107906 | lifeskim:mentions | umls-concept:C0205195 | lld:lifeskim |
| pubmed-article:17107906 | lifeskim:mentions | umls-concept:C1704419 | lld:lifeskim |
| pubmed-article:17107906 | lifeskim:mentions | umls-concept:C1523987 | lld:lifeskim |
| pubmed-article:17107906 | lifeskim:mentions | umls-concept:C1589416 | lld:lifeskim |
| pubmed-article:17107906 | pubmed:issue | 11 | lld:pubmed |
| pubmed-article:17107906 | pubmed:dateCreated | 2006-11-19 | lld:pubmed |
| pubmed-article:17107906 | pubmed:abstractText | A retrospective case-matched study was conducted to compare the oral regimen CTD (cyclophosphamide - thalidomide - dexamethasone) and infusional CVAMP (cyclophosphamide - vincristine - doxorubicin - methylprednisolone) as induction therapy followed by autologous peripheral blood stem-cell transplantation (PBSCT) for newly diagnosed multiple myeloma patients. The response rate after three cycles of treatment was statistically higher with CTD (n = 27) compared to CVAMP (n = 27) (89% vs. 56%, P = 0.016). Toxicity studies showed more neutropenia (grade 3/4) (4% vs. 60%, P = 0.0002) with CVAMP and more thrombotic episodes with CTD (11% vs. 4%). CTD may emerge as the superior induction regimen prior to PBSCT, in terms of high efficacy and better tolerability. | lld:pubmed |
| pubmed-article:17107906 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17107906 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17107906 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17107906 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17107906 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17107906 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17107906 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17107906 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17107906 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17107906 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17107906 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17107906 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17107906 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:17107906 | pubmed:issn | 1042-8194 | lld:pubmed |
| pubmed-article:17107906 | pubmed:author | pubmed-author:WuPingP | lld:pubmed |
| pubmed-article:17107906 | pubmed:author | pubmed-author:DaviesFaith... | lld:pubmed |
| pubmed-article:17107906 | pubmed:author | pubmed-author:MorganGareth... | lld:pubmed |
| pubmed-article:17107906 | pubmed:author | pubmed-author:PotterMichael... | lld:pubmed |
| pubmed-article:17107906 | pubmed:author | pubmed-author:AlvaresCaroli... | lld:pubmed |
| pubmed-article:17107906 | pubmed:author | pubmed-author:TreleavenJenn... | lld:pubmed |
| pubmed-article:17107906 | pubmed:author | pubmed-author:HortonCliveC | lld:pubmed |
| pubmed-article:17107906 | pubmed:author | pubmed-author:SasoRadovanR | lld:pubmed |
| pubmed-article:17107906 | pubmed:author | pubmed-author:EthellMark... | lld:pubmed |
| pubmed-article:17107906 | pubmed:author | pubmed-author:KrishnanBijuB | lld:pubmed |
| pubmed-article:17107906 | pubmed:author | pubmed-author:JennerMatthew... | lld:pubmed |
| pubmed-article:17107906 | pubmed:author | pubmed-author:McCormackRita... | lld:pubmed |
| pubmed-article:17107906 | pubmed:author | pubmed-author:DinesSharonS | lld:pubmed |
| pubmed-article:17107906 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17107906 | pubmed:volume | 47 | lld:pubmed |
| pubmed-article:17107906 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17107906 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17107906 | pubmed:pagination | 2335-8 | lld:pubmed |
| pubmed-article:17107906 | pubmed:meshHeading | pubmed-meshheading:17107906... | lld:pubmed |
| pubmed-article:17107906 | pubmed:meshHeading | pubmed-meshheading:17107906... | lld:pubmed |
| pubmed-article:17107906 | pubmed:meshHeading | pubmed-meshheading:17107906... | lld:pubmed |
| pubmed-article:17107906 | pubmed:meshHeading | pubmed-meshheading:17107906... | lld:pubmed |
| pubmed-article:17107906 | pubmed:meshHeading | pubmed-meshheading:17107906... | lld:pubmed |
| pubmed-article:17107906 | pubmed:meshHeading | pubmed-meshheading:17107906... | lld:pubmed |
| pubmed-article:17107906 | pubmed:meshHeading | pubmed-meshheading:17107906... | lld:pubmed |
| pubmed-article:17107906 | pubmed:meshHeading | pubmed-meshheading:17107906... | lld:pubmed |
| pubmed-article:17107906 | pubmed:meshHeading | pubmed-meshheading:17107906... | lld:pubmed |
| pubmed-article:17107906 | pubmed:meshHeading | pubmed-meshheading:17107906... | lld:pubmed |
| pubmed-article:17107906 | pubmed:meshHeading | pubmed-meshheading:17107906... | lld:pubmed |
| pubmed-article:17107906 | pubmed:meshHeading | pubmed-meshheading:17107906... | lld:pubmed |
| pubmed-article:17107906 | pubmed:meshHeading | pubmed-meshheading:17107906... | lld:pubmed |
| pubmed-article:17107906 | pubmed:meshHeading | pubmed-meshheading:17107906... | lld:pubmed |
| pubmed-article:17107906 | pubmed:meshHeading | pubmed-meshheading:17107906... | lld:pubmed |
| pubmed-article:17107906 | pubmed:meshHeading | pubmed-meshheading:17107906... | lld:pubmed |
| pubmed-article:17107906 | pubmed:meshHeading | pubmed-meshheading:17107906... | lld:pubmed |
| pubmed-article:17107906 | pubmed:meshHeading | pubmed-meshheading:17107906... | lld:pubmed |
| pubmed-article:17107906 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:17107906 | pubmed:articleTitle | The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide - vincristine - doxorubicin - methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis. | lld:pubmed |
| pubmed-article:17107906 | pubmed:affiliation | Haemato-Oncology Unit, Royal Marsden Hosptial, Sutton, Surrey, UK. | lld:pubmed |
| pubmed-article:17107906 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17107906 | lld:pubmed |
